このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Transgene マネジメント

マネジメント基準チェック /24

Transgene'sの CEO はAlessandro Rivaで、 Jun2023年に任命され、の在任期間は 1.08年です。の年間総報酬は€ 510.00Kで、 68.6%給与と31.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.029%を直接所有しており、その価値は€ 31.09K 。経営陣と取締役会の平均在任期間はそれぞれ1.1年と4.5年です。

主要情報

Alessandro Riva

最高経営責任者

€510.0k

報酬総額

CEO給与比率	68.6%
CEO在任期間	1.3yrs
CEOの所有権	0.02%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	4.7yrs

経営陣の近況

Recent updates

Is Transgene (EPA:TNG) Using Too Much Debt?

Jun 15

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Mar 21

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Jan 23

CEO報酬分析

Transgene の収益と比較して、Alessandro Riva の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	€510k	€350k	-€22m
Sep 30 2023	n/a	n/a	-€28m
Jun 30 2023	n/a	n/a	-€33m
Mar 31 2023	n/a	n/a	-€33m
Dec 31 2022	€304k	n/a	-€33m

報酬と市場: Alessandroの総報酬 ($USD 568.82K ) は、 French市場 ($USD 481.13K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Alessandroの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Alessandro Riva (63 yo)

1.3yrs

在職期間

€510,000

報酬

Dr. Alessandro Riva, M.D., serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2023. He serves as Independent Non-Executive Director at BeiGene, Ltd. since February 01...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Alessandro Riva	CEO & Chairman of the Board	1.3yrs	€510.00k	0.022% € 32.1k
Lucie Larguier	Chief Financial Officer	less than a year	データなし	データなし
John Felitti	VP, General Counsel & Corporate Secretary	8.5yrs	データなし	データなし
Christelle Schwoerer	Chief Human Resources Officer	less than a year	データなし	データなし
James Wentworth	VP & Chief Business Officer	less than a year	データなし	データなし
Gaelle Stadtler	VP & Director of Human Resources	no data	データなし	データなし
Kaidre Bendjama	Project Leader of Personalized Cancer Vaccines	no data	データなし	データなし

0.7yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: TNGの経営陣は経験豊富とはみなされません ( 0.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Alessandro Riva	CEO & Chairman of the Board	2.3yrs	€510.00k	0.022% € 32.1k
Benoit Habert	Director	24.7yrs	€34.00k	0.078% € 112.8k
Alain Merieux	Honorary Chairman	4.7yrs	データなし	69.27% € 100.2m
Jean-Luc Belingard	Non-Independent Director	11.3yrs	データなし	データなし
Philippe Archinard	Director	19.8yrs	データなし	0.43% € 618.9k
Jean-Yves Blay	Independent Director	2.3yrs	€21.00k	データなし
John Bell	Member of Scientific Advisory Board	1.5yrs	データなし	データなし
Pedro Romero	Member of Scientific Advisory Board	no data	データなし	データなし
Marie-Yvonne Landel-Meunier	Independent Director	7.3yrs	€53.00k	データなし
Carol Stuckley	Independent Director	1.3yrs	データなし	データなし
Maya Said	Independent Director	7.3yrs	€75.00k	データなし
Sandrine Flory	Director	3.7yrs	データなし	データなし

4.7yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: TNGの取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

Transgene マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Less than half of directors are independent

Transgene SA Announces Chief Financial Officer Changes

Transgene SA Appoints Carol Stuckley as Independent Director

Transgene SA Approves Board and Committee Changes

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Recent updates

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

Consensus revenue estimates fall by 45%

Is Transgene (EPA:TNG) Using Too Much Debt?

New major risk - Financial position

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

Price target decreased by 11% to €3.50

New major risk - Financial position

Consensus revenue estimates fall by 23%

Price target decreased by 7.6% to €3.67

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Consensus revenue estimates fall by 15%

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released: EPS: €0 (vs €0.14 loss in 1H 2021)

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Consensus forecasts updated

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Consensus forecasts updated

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day high: €2.70

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.77

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

New 90-day high: €1.75

Transgene Appoints Hedi Ben Brahim as Chief Executive Officer, Effective January 1, 2021

First half 2020 earnings released: €0.03 loss per share

マネジメント基準チェック /24